Genenta Science announced on July 1, 2025, long-term follow-up observations from its glioblastoma multiforme (GBM) study, revealing emerging survival signals. A total of 38 patients were enrolled in the TEM-GBM study, with 25 receiving Temferon.
Two patients enrolled in the TEM-LT long-term follow-up study have survived three years from the time of their first surgery. One of these long-term survivors has not experienced disease progression following Temferon administration and has not required any second-line therapies, while the other showed initial signs of progression that subsequently stabilized without additional intervention.
As of the April data cutoff, the two-year survival rate in the GBM trial for unmethylated MGMT (uMGMT) patients remained consistent at 29%, with median overall survival holding steady at 17 months. These results continue to compare favorably to historical cohorts, where uMGMT patients receiving standard of care typically show a two-year survival rate of approximately 14% and a median overall survival of 13 to 15 months.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.